Reasons and treatment strategy for discontinuation of dapoxetine treatment in premature ejaculation patients in China: A retrospective observational study
- PMID: 35324028
- DOI: 10.1111/and.14425
Reasons and treatment strategy for discontinuation of dapoxetine treatment in premature ejaculation patients in China: A retrospective observational study
Abstract
To assess dapoxetine discontinuation rates and the reasons for discontinuation in Chinese men with premature ejaculation (PE). Information on 906 PE outpatients was obtained from the hospital information system (HIS) in 2019. Of these, 150 patients were chosen. We analysed the dapoxetine discontinuation rate and the reasons for discontinuation over a 12-week follow-up period. The mean age of all patients was 33.6 years (range = 18-55), the mean PE duration was 12.36 ± 9.45 months. The 5-item International Index of Erectile Function (IIEF-5) score was 21.51 ± 3.80. A total of 37.3% of all the patients remained on the treatment until the 12th week. The cumulative discontinuation rates at the 4th, 8th and 12th weeks were 12%, 41.3% and 62.7%, respectively. The discontinuation rates for all the patients in weeks 0-4, weeks 4-8 and weeks 8-12 were 19.1%, 46.8% and 34.0%, respectively. After 4 weeks, the discontinuation rates dropped sharply. The reasons for patients' discontinuation were as follows: overexpectation of efficacy (30.9%), relapsing after drug withdrawal (26.6%), high cost (25.5%), side effects (9.6%), fear of drug addiction (4.3%), failure of follow-up (2.1%) and choosing other treatments (1.1%). The dapoxetine treatment discontinuation rate was very high. The main reasons for discontinuation were overexpectation of efficacy and high cost.
Keywords: dapoxetine; discontinuation; premature ejaculation; reason.
© 2022 Wiley-VCH GmbH.
Similar articles
-
Efficacy and safety of dapoxetine in men with premature ejaculation and concomitant erectile dysfunction treated with a phosphodiesterase type 5 inhibitor: randomized, placebo-controlled, phase III study.J Sex Med. 2013 Sep;10(9):2312-25. doi: 10.1111/jsm.12236. Epub 2013 Jul 11. J Sex Med. 2013. PMID: 23845016 Clinical Trial.
-
Dapoxetine treatment in patients with lifelong premature ejaculation: the reasons of a "Waterloo".Urology. 2013 Sep;82(3):620-4. doi: 10.1016/j.urology.2013.05.018. Urology. 2013. PMID: 23987156 Clinical Trial.
-
Antidepressant treatment of premature ejaculation: discontinuation rates and prevalence of side effects for dapoxetine and paroxetine in a naturalistic setting.Int J Impot Res. 2015 Mar-Apr;27(2):75-80. doi: 10.1038/ijir.2014.37. Epub 2014 Nov 20. Int J Impot Res. 2015. PMID: 25410962
-
Efficacy and safety of dapoxetine in treatment of premature ejaculation: an evidence-based review.Int J Clin Pract. 2016 Sep;70(9):723-33. doi: 10.1111/ijcp.12843. Epub 2016 Jul 25. Int J Clin Pract. 2016. PMID: 27456527 Review.
-
Efficacy of Dapoxetine for the treatment of premature ejaculation: a meta-analysis of randomized clinical trials on intravaginal ejaculatory latency time, patient-reported outcomes, and adverse events.Urology. 2015 Apr;85(4):856-61. doi: 10.1016/j.urology.2015.01.009. Urology. 2015. PMID: 25817107 Review.
Cited by
-
Daily intake of 30 mg duloxetine is effective in decreasing premature ejaculation severity: a prospective randomized placebo-controlled cross over clinical trial.Basic Clin Androl. 2023 Dec 5;33(1):34. doi: 10.1186/s12610-023-00210-1. Basic Clin Androl. 2023. PMID: 38049720 Free PMC article.
References
REFERENCES
-
- Alghobary, M., Gaballah, M., El-Kamel, M. F., State, A. F., Ismail, S. R., Selim, M. K., & Mostafa, T. (2020). Oral dapoxetine versus topical lidocaine as on-demand treatment for lifelong premature ejaculation: A randomised controlled trial. Andrologia, 52(5), e13558. https://doi.org/10.1111/and.13558
-
- Castiglione, F., Albersen, M., Hedlund, P., Gratzke, C., Salonia, A., & Giuliano, F. (2016). Current pharmacological management of premature ejaculation: A systematic review and meta-analysis. European Urology, 69(5), 904-916. https://doi.org/10.1016/j.eururo.2015.12.028
-
- Cevolani, D. (2020). Editorial for "Altered functional connectivity of hypothalamus in lifelong premature ejaculation patients". Journal of Magnetic Resonance Imaging, 52(3), 785-786. https://doi.org/10.1002/jmri.27128
-
- Colonnello, E., Ciocca, G., Limoncin, E., Sansone, A., & Jannini, E. A. (2021). Redefining a sexual medicine paradigm: Subclinical premature ejaculation as a new taxonomic entity. Nature Reviews Urology, 18(2), 115-127. https://doi.org/10.1038/s41585-020-00417-1
-
- Gray, M., Zillioux, J., Khourdaji, I., & Smith, R. P. (2018). Contemporary management of ejaculatory dysfunction. Translational Andrology and Urology, 7(4), 686-702. https://doi.org/10.21037/tau.2018.06.20
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources